Pharmaceutical Industry

CRAZYPETS GmbH 

Wil Sg · Since 2017

The core activity of CRAZYPETS GmbH is the development and implementation of private label product ranges for dogs and cats, particularly in the areas of: Anti-parasitic and biocidal products, Oral care, Skin and coat care, Dietary supplements, Environmental hygiene. The company supports customers in developing products and product ranges tailored to their specific needs and offers services such as product development, packaging design and labeling.

CRISPR Therapeutics AG 

Zug · Since 2013

The core activity of CRISPR Therapeutics is the development of gene therapeutic medicines, particularly through the application of CRISPR-Cas9 technology, to cure diseases at the molecular level. The company focuses on developing medicines for various diseases such as sickle cell anemia, β-thalassemia, cancer, autoimmune disorders, and regenerative medicine.

Cronet Sagl 

Chiasso · Since 2015

The core activity of Cronet Sagl is consulting and project management for pharmaceutical research and development projects (R&D). The company supports customers in the development of medicinal products and medical devices by leveraging its long-standing experience and collaboration with international laboratories and experts. The services include project and study planning, selection and monitoring of Contract Research Organizations (CRO), document review, support in approval procedures and communication with regulatory authorities.

CROSS PHARM SA 

Geneva · Since 2013

The core activity of Cross Pharm S.A. is the development, manufacture and marketing of high-quality medicines, including antibiotics, antiemetics, muscle relaxants, orexigenics and vitamins as well as minerals.

Curatis AG 

Liestal · Since 1993

Curatis AG is a specialty pharmaceutical company focused on acquiring, developing and commercialising medicines for the prevention, diagnosis and treatment of rare and specialty‑care diseases. The company operates a distribution business for third‑party orphan and specialty medicines and a development business advancing proprietary drug candidates (e.g., C‑PTBE‑01, C‑AM‑01, C‑MOH‑01, C‑FI‑01) toward clinical development.

Curaxon AG 

Oetwil An Der Limmat · Since 2020

The core activity of Curaxon Ltd. is the development and marketing of innovative drugs for the treatment of neurodegenerative diseases of the central nervous system (CNS), particularly those with high medical need and insufficient therapeutic options. To this end, the company modifies existing active ingredients to improve their pharmacokinetic and pharmacodynamic properties and to exploit new mechanisms of action in order to achieve higher therapeutic efficacy.

Cures Healthcare Ltd 

Lugano · Since 2012

The core activity of Cures Health Care is the development, manufacture and export of pharmaceutical products, particularly generics and biosimilars, of both Swiss and non-Swiss origin. The company offers a wide range of medications, including tablets, capsules and injectable products, used to treat various diseases and conditions, such as hypertension, diabetes, anxiety disorders and cancer. Cures Health Care operates in over 12 countries worldwide, including the MENA region, Europe, the US and Canada, and collaborates with local licensees and government authorities to offer its products on the respective markets.

Partex.AI Therapeutics AG 

Cham · Since 2024

The core activity of Cureteq consists of two main areas: 1. **Asset Management**: The company offers services in the field of asset management, which indicates that it is involved in the management and optimization of assets, such as financial investments or company participations. 2. **Biotechnology**: Cureteq is also active in biotechnology, which indicates that it is involved in the development and application of biotechnological processes and products, such as the development of medicines or the application of genetic engineering. Both areas are supported by the application of **artificial intelligence (AI)**, which indicates that the company uses AI technologies to optimize and improve its activities.

Daiichi Sankyo (Schweiz) AG 

Zurich · Since 1998

Daiichi Sankyo is a pharmaceutical company specializing in the development, production, and distribution of pharmaceutical products. The company's core activity lies in the research, development, and provision of medicines and health products, particularly in the field of antithrombotics. The company also offers additional services such as digital solutions for communication between doctors and patients, as well as training platforms for healthcare professionals.

DalCor Pharma UK Ltd., Leatherhead, Zweigniederlassung Zug 

Zug · Since 2015

The core activity of DalCor Pharmaceuticals is the development and research of medicines for the treatment of cardiovascular diseases, particularly through the application of precision medicine. The company focuses on developing therapies to combat the world's largest health burden, cardiovascular diseases.

DAMIAN PHARMA AG 

Walchwil · Since 2014

The core activity of DAMIAN PHARMA AG is the development and marketing of pharmaceutical products, in particular the development of therapies for rare diseases such as Primary Aldosteronism (PA).

Darosan GmbH 

Birmenstorf Ag · Since 2021

The core activity of Darosan GmbH is the development, manufacture and distribution of dietary supplements and pharmaceutical products, in particular those based on micelle technology, which serve to support the health and quality of life of people with chronic diseases, weakened immune systems and/or inflammation.

Dayton Therapeutics AG 

Steinhausen · Since 2020

The core activity of Dayton Therapeutics AG is the development and application of therapeutics, particularly in the field of oncology, using digital and artificial intelligence technologies. The company is also active in investing in and advising life science companies, particularly in the areas of biotechnology and medical technology.

DeepVax GmbH 

Rämismühle · Since 2018

The core activity of DeepVax GmbH is the development, manufacture and marketing of innovative therapeutic vaccines against chronic inflammatory diseases, obesity, aging and cancer.

Dehly S.A. 

Marly · Since 1985

The core activity of Dehly SA is the development, manufacture and marketing of pharmaceutical lozenges, particularly based on gum arabic and plant-based ingredients. The company also offers services such as product development, prototype production, sensory testing and support for product registration.

Denali Therapeutics CH GmbH 

Zurich · Since 2024

Denali Therapeutics CH GmbH is a biopharmaceutical company that discovers, develops and delivers biotherapeutics intended to treat serious diseases affecting the brain and the body. It developed the TransportVehicle™ platform to enable systemic delivery of enzymes, oligonucleotides and antibodies across the blood–brain barrier and is advancing a pipeline for neurodegenerative and lysosomal storage disorders.

Dermapharm AG 

Hünenberg · Since 1995

The core activity of Dermapharm AG is the manufacture, development and distribution of high-quality dermatological and anti-inflammatory drugs, particularly in the field of skin health and allergies.

Dermavant Sciences GmbH 

Lucerne · Since 2016

The core activity of Dermavant Sciences is the development and marketing of innovative therapeutics in immuno-dermatology, particularly for the treatment of skin diseases such as psoriasis, atopic dermatitis, vitiligo and hyperhidrosis.

Desaturase SA 

Anières · Since 2003

The core activity of Desaturase SA is the development, manufacture and marketing of dietary supplements, particularly vitamins, minerals and other nutrients in the form of capsules, gelules and powders.

Desitin Pharma GmbH 

Liestal · Since 1997

The core activity of Desitin Pharma GmbH is the development, manufacture and marketing of pharmaceuticals, particularly in the therapeutic area of epilepsy. The company focuses on the galenics of medications and offers innovative dosage forms that facilitate intake and increase compliance.